openPR Logo
Press release

Anticonvulsants for Neuropathic Pain Market Sluggish Growth Rate Foreseen by 2017-2025

08-22-2019 01:41 PM CET | Health & Medicine

Press release from: TMR Research

TMR Research

TMR Research

Global Anticonvulsants for Neuropathic Pain Market: Snapshot

Neuropathic pain, which refers to kind of chronic pain resulting from an injury to or disease of the central or peripheral nervous system, remains a therapeutic challenge to clinicians as it does not respond well to conventional pain therapies. Although the clinical knowledge regarding the pathogenesis of the condition has significantly increased over the past few decades, the actual mode of action of most popular treatment mechanisms and the pathogenesis of neuropathic pain remain somewhat unclear.

Get Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=32

Owing to the several similarities between the pathophysiological symptoms observed in neuropathic pain models and in some epilepsy models, anticonvulsants are finding increased usage in the symptomatic management of neuropathic pain conditions. Carbamazepine, the world’s first anticonvulsant examined in clinical trials, continues to remain one of the key choices of healthcare practitioners for neuropathic pain conditions. Apart from carbamazepine, a number of new anticonvulsants in the anticonvulsants for neuropathic pain market or in high quality clinical trials represent a new era in the treatment of neuropathic pain.

The overall role of anticonvulsants in the treatment of neuropathic pain continues to evolve. Further advances in the overall understanding of the mechanisms of neuropathic pain conditions and well-designed clinical trials are expected to further improve the opportunities to make anticonvulsants an established course of action in the treatment of neuropathic pain. This report examines the current state of development of the global anticonvulsants for neuropathic pain market, with applications in the treatment of neuropathic pain at the center of focus. Recent developments and future scope of development of the anticonvulsants for neuropathic pain market are also analyzed.

Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=32

Global Anticonvulsants for Neuropathic Pain Market: Overview

Neurapthic pain (NP) is a severe pain associated with a number of diseases such as cancer, diabetes, and herpes zoster. This pain affects almost 1% of the world’s total population and is aggravated as a result of dysfunction, lesion, or transitory perturbation in the peripheral and central nervous system. Some other causes of neuropathic pain include trigeminal neuralgia, peripheral and entrapment neuropathy, brachial plexus avulsion pain, spinal cord injury pain, post-herpetic neuralgia, arachnoiditis, phantom limb pain, and post-stroke pain.

The report presents a definitive analysis of market drivers, market restraints, and trends that will impact progression of the global anticonvulsants for neuropathic pain market until the end of 2025. The report charts the developmental growth map in the future by analyzing the past performance of the market.

The research report analyzes the global anticonvulsants for neuropathic pain market from a competitive viewpoint as well. The report finds out how innovations and product development will present growth opportunities to market players to serve niche patient areas. The analysis of changing competitive hierarchy is presented through graphs and pictorial representations. The report is compiled after collecting data from industry-centric databases and scrutinized using validated analytical tools.

Global Anticonvulsants for Neuropathic Pain Market: Drivers and Restraints

The increasing incidence of people with neuropathic pain is one of the major factors driving the anticonvulsants for neuropathic pain market. In addition, a high number of patients refractory to alternate treatment methods, increasing use of generic drugs compared to branded drugs, and a high rate of polypharmacy are some other factors driving the growth of this market.

The development of novel drug molecules for neuropathic drug indications is also propelling the growth of this market. This is because less than 50% of the patients respond to existing drugs that are available for neuropathic drug indications. Moreover, these drugs are associated with a number of side effects, particularly when administered systemically. Hence, new drug variants that can provide convincing action mechanism will be a game changer in the global anticonvulsants for neuropathic pain market.

Some of the newer anticonvulsant drugs for neuropathic pain include Depomed’s Gralise (gabapentin gastric-retention), which is available since 2011 and is a ‘once –daily’ formulation. XenoPort’s Horizant (gabapentin encarbil) was introduced in 2012 and is a “twice-daily’ formulation.

Global Anticonvulsants for Neuropathic Pain Market: Advantages of Anticonvulsants

Neuropathic pain can be managed by opioids such as morphine, non-steroidal anti-inflammatory drugs, and anticonvulsant drugs. Anticonvulsants are normally used to control epileptic seizures but may also be used for treating neuropathic pain conditions such as fibromyalgia and postherpetic neuralgia. Anticonvulsants impede seizures through multiple mechanisms such as:

Functional obstruction of voltage-gated-calcium channels
Impediment of glutamergic neurotransmission
Functional obstruction of voltage-sodium channels
Direct or indirect enhancement of hindering GABAergic neurotransmission

Companies Mentioned in report

The report provides a detailed vendor landscape of the global anticonvulsants for neuropathic pain market with a business profile of major companies that operate in this market. These are Teva Pharmaceuticals, Depomed Inc., Janssen Pharmaceutical Inc., Cephalon Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., AbbVie Inc., and XenoPort Inc.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,
3739 Balboa St # 1097,
San Francisco, CA 94121
United States
Tel: +1-415-520-1050

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anticonvulsants for Neuropathic Pain Market Sluggish Growth Rate Foreseen by 2017-2025 here

News-ID: 1825053 • Views: 189

More Releases from TMR Research

KEY OPINION LEADER MANAGEMENT MARKET SCOPE, SEGMENTATION, DEVELOPMENT AND OPPORT …
Global Key Opinion Leader Management Market: Snapshot Key opinion leaders (KOLs) are trustworthy, influential, and experts of a particular field in the healthcare industry. Relationships of a firm with these KOLs is of great importance to manage and build a strong healthcare profile. These key opinion leaders go a long way towards educating the scientific and medical communities as well as help in increasing awareness pertaining to the recent developments in
SMART WATER GRID MARKET NEWER SEGMENTS OF APPLICATION 2025
Global Smart Water Grid Market – Snapshot The global smart water grid market is foreseen to experience its development prodded on the back of the prerequisite of managing old infrastructure, rise in information and communication technology (ICT), gap between supply and demand, water shortage, and several other factors. So as to guarantee smooth supply of water and keep a tab on its equal supply, smart water grid technology is expected to
DIGITAL UTILITY MARKET EXPANSION PROJECTED TO GAIN AN UPTICK DURING 2025
Global Digital Utility Market: Snapshot In the midst of surging demand for quick digitalization and green energy in the energy segment, the interest for digital utility system is rising notably. Penetration of digital innovations in the vitality sector and programs in nations, for example, India and China expected to fulfil local needs are foreseen to feed the demand for digital utility solutions. Get Exclusive PDF Sample Copy Of This Report: https://www.tmrresearch.com/sample/sample?flag=B&rep_id=3398 Rise in
WEB CONTENT MANAGEMENT MARKET VALUE PROJECTED TO EXPAND BY 2025
Global Web Content Management Market: Snapshot The global web content management market is anticipated to gain impetus due to the need for organizing and appropriately using content across various marketing channels such as social media and mobile, and not just the web. Web content management allows users to have a seamless web experience while helping organizations to digitally market their products and services. It helps both technical and non-technical users to

All 5 Releases


More Releases for Anticonvulsants

Generic and branded anticonvulsants are restraining the growth of novel therapie …
Anticonvulsants, also commonly known as antiepileptic drugs or antiseizure drugs are a diverse group of pharmacology agents used in the treatment of epileptic seizures. Epilepsy is a chronic disorder resulting in repeated and unprovoked seizures. Epileptic seizures are commonly referred as convulsions. Anticonvulsants are mainly used for treatment of epileptic seizures. Epileptic seizures are caused by disturbance in the electrical activity of the brain. In addition, anticonvulsants are also used
Epileptic Anticonvulsants Market Size, Growth, Trends and 2020 Forecast Report
According to the WHO, nearly 80% of epilepsy patients are found in developing regions. However, developed regions are dominant in the global epileptic anticonvulsants market. Currently, North America dominates the epileptic anticonvulsants market, followed by Europe. Highly developed healthcare infrastructure, high level of awareness, high healthcare spending on epilepsy and related treatments, along with availability of skilled professionals to treat epilepsy are driving the North America and Europe epileptic anticonvulsants
Anticonvulsants for Neuropathic Pain Market unprovoked by 2025
Global Anticonvulsants for Neuropathic Pain Market: Snapshot Neuropathic pain, which refers to kind of chronic pain resulting from an injury to or disease of the central or peripheral nervous system, remains a therapeutic challenge to clinicians as it does not respond well to conventional pain therapies. Although the clinical knowledge regarding the pathogenesis of the condition has significantly increased over the past few decades, the actual mode of action of most
Anticonvulsants for Neuropathic Pain Market Business Strategy & Forecast by 2025
Global Anticonvulsants for Neuropathic Pain Market: Snapshot Neuropathic pain, which refers to kind of chronic pain resulting from an injury to or disease of the central or peripheral nervous system, remains a therapeutic challenge to clinicians as it does not respond well to conventional pain therapies. Although the clinical knowledge regarding the pathogenesis of the condition has significantly increased over the past few decades, the actual mode of action of most
Anticonvulsants Drug Market - Significant Growth During 2025
The first line of treatment in pain management usually involves the use of pharmaceuticals from various therapeutic classes such as antidepressants, opioids, NSAIDs, anticonvulsants, anesthetics, and other non-narcotic analgesics. Anticonvulsants, also known as antiepileptic drugs, were developed primarily for the treatment of epileptic seizures. However, leading anticonvulsant drugs such as Lyrica (pregabalin) and Neurontin (gabapentin) have also been approved for the management of various pain indications including fibromyalgia, migraine and
Anticonvulsants Drug Market Research Report by Key Players Analysis 2025
The first line of treatment in pain management usually involves the use of pharmaceuticals from various therapeutic classes such as antidepressants, opioids, NSAIDs, anticonvulsants, anesthetics, and other non-narcotic analgesics. Anticonvulsants, also known as antiepileptic drugs, were developed primarily for the treatment of epileptic seizures. However, leading anticonvulsant drugs such as Lyrica (pregabalin) and Neurontin (gabapentin) have also been approved for the management of various pain indications including fibromyalgia, migraine and